Advertisement
Advertisement
ECOR
electroCore, Inc. Common Stock
8.09
USDSponsored
+1.39
+20.75%
Aug 07, 15:59 UTC -4
Closed
After-Market
7.82
-0.27
-3.40%
ECOR Earnings Reports
Positive Surprise Ratio
ECOR beat 21 of 33 last estimates.
64%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$11.07M
/-$0.29
Implied change from Q2 26 (Revenue/ EPS)
+17.16%
/-12.12%
Implied change from Q3 25 (Revenue/ EPS)
+27.42%
/-27.50%
electroCore, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, ECOR reported earnings of -0.33 USD per share (EPS) for Q2 26, beating the estimate of -0.43 USD, resulting in a 23.40% surprise. Revenue reached 9.45 million, compared to an expected 9.68 million, with a -2.38% difference. The market reacted with a +20.75% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.29 USD, with revenue projected to reach 11.07 million USD, implying an decrease of -12.12% EPS, and increase of 17.16% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Profound Medical Corp. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
$0.26
Surprise
+199.01%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.48
Surprise
-24.93%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Relay Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.41
Surprise
-2.78%
FAQ
What were electroCore, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, electroCore, Inc. Common Stock reported EPS of -$0.33, beating estimates by 23.4%, and revenue of $9.45M, -2.38% below expectations.
How did the market react to electroCore, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 20.75%, changed from $6.70 before the earnings release to $8.09 the day after.
When is electroCore, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for electroCore, Inc. Common Stock's next earnings report?
Based on 6
analysts, electroCore, Inc. Common Stock is expected to report EPS of -$0.29 and revenue of $11.07M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement